Spesolimab is currently in clinical development for the treatment of acute flares of generalised pustular psoriasis (GPP). Individuals with GPP experience repeated episodes where large surface areas of the skin become inflamed and red, and develop small pus-filled blisters known as pustules. It is a disease that spreads and affects a large surface area of the body. The main cause of GPP is not yet known but it is thought that environmental factors such as stress and genetic susceptibility can trigger disease onset. GPP can be a life-threatening disease if left untreated as it can lead to organ failure. Spesolimab is administered intravenously for the treatment of flares of GGP . It blocks the interaction of interleukin 36 receptor (IL-36R) and IL-36 which also blocks downstream inflammatory responses. Many patients with moderate to severe GPP struggle with insufficient disease control. There is currently no biologic treatment for GPP. If licensed spesolimab will offer a new treatment option for patients with flares of GPP.